Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 12/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6093632 | 1.00 | PTGS2 (0.50) | PTGS2PTGS1USP2POLBMAPT | |
| SCHEMBL29527861 | 1.00 | PTGS2 (0.50) | PTGS2PTGS1USP2POLBMAPT | |
| SCHEMBL29527819 | 0.86 | PTGS2 (0.56) | PTGS2PTGS1MAPTMEN1KMT2A | |
| SCHEMBL215548 | 0.86 | PTGS2 (0.56) | PTGS2PTGS1MAPTMEN1KMT2A | |
| SCHEMBL6092332 | 0.86 | PTGS2 (0.56) | PTGS2PTGS1MAPTMEN1KMT2A | |
| SCHEMBL7140451 | 0.86 | MEN1 (0.46) | USP2POLBMAPTMEN1KMT2A | |
| SCHEMBL27470724 | 0.82 | PTGS2 (0.45) | PTGS2PTGS1 | |
| SCHEMBL29528338 | 0.80 | PTGS2 (0.54) | PTGS2PTGS1MAPTMEN1KMT2A | |
| SCHEMBL6093446 | 0.80 | PTGS2 (0.54) | PTGS2PTGS1MAPTMEN1KMT2A | |
| SCHEMBL214099 | 0.80 | PTGS2 (0.54) | PTGS2PTGS1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 294 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9447065-B2 | Pharmaceutical composition | RAQUALIA PHARMA INC. (JP) | 2016-09-20 | — | — | US | claimed |
| EP-2979695-A1 | THERAPEUTIC AGENT FOR EYE DISORDER | AskAt Inc. (JP) | 2016-02-03 | — | — | EP | claimed |
| US-20160008317-A1 | THERAPEUTIC AGENT FOR OCULAR DISEASE | ASKAT INC. (JP) | 2016-01-14 | — | — | US | claimed |
| US-20140256804-A1 | PHARMACEUTICAL COMPOSITION | RAQUALIA PHARMA INC. (JP) | 2014-09-11 | — | — | US | claimed |
| EP-2769718-A1 | MEDICINAL COMPOSITION | RaQualia Pharma Inc. (JP) | 2014-08-27 | — | — | EP | claimed |
| EP-1725222-A2 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PSYCHIATRIC DISORDERS WITH COX-2 INHIBITORS ALONE AND IN COMBINATION WITH ANTIDEPRESSANT AGENTS | Pharmacia Corporation (US) | 2006-11-29 | — | — | EP | claimed |
| EP-1691797-A2 | COMBINATION OF CYCLOOXYGENASE-2 INHIBITOR AND PHOSPHODIESTERASE 4 INHIBITOR AND METHOD | Pharmacia Corporation (US) | 2006-08-23 | — | — | EP | claimed |
| EP-1575594-A2 | COMBINATION OF REBOXETINE AND A CYCLOOXYGENASE-2 INHIBITOR | Pharmacia Corporation (US) | 2005-09-21 | — | — | EP | claimed |
| WO-2005084654-A2 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PSYCHIATRIC DISORDERS WITH COX-2 INHIBITORS ALONE AND IN COMBINATION WITH ANTIDEPRESSANT AGENTS | PHARMACIA CORPORATION (US) | 2005-09-15 | — | — | WO | claimed |
| EP-1536863-A1 | USE OF CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND THROMBOLYTIC AGENTS FOR THE TREATMENT OR PREVENTION OF A VASO-OCCLUSIVE EVENT | Pharmacia Corporation (US) | 2005-06-08 | — | — | EP | claimed |
| EP-0977748-B1 | SUBSTITUTED BENZOPYRAN DERIVATIVES FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 2003-03-26 | — | — | EP | claimed |
| WO-2003015608-A2 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | SUGEN, INC. (US) | 2003-02-27 | — | — | WO | claimed |
| WO-2003015797-A1 | COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF PAIN AND INFLAMMATION WITH A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND GLUCOSAMINE | PHARMACIA CORPORATION (US) | 2003-02-27 | — | — | WO | claimed |
| WO-2002096516-A1 | USE OF COMPOSITIONS COMPRISING CYCLOOXYGENASE-2 SELECTIVE INHIBITORS IN COMBINATION WITH RADIATION FOR INHIBITION OR PREVENTION OF CARDIOVASCULAR DISEASE | PHARMACIA CORPORATION (US) | 2002-12-05 | — | — | WO | claimed |
| WO-2002085459-A2 | ANTIANGIOGENIC COMBINATION THERAPY FOR THE TREATMENT OF CANCER | PHARMACIA CORPORATION (US) | 2002-10-31 | — | — | WO | claimed |
| WO-2002078626-A2 | THERAPEUTIC COMBINATIONS FOR CARDIOVASCULAR AND INFLAMMATORY INDICATIONS | PHARMACIA CORPORATION (US) | 2002-10-10 | — | — | WO | claimed |
| US-20020103141-A1 | Antiangiogenic combination therapy for the treatment of cancer | PHARMACIA CORPORATION | 2002-08-01 | — | — | US | claimed |
| US-20020077328-A1 | Selective cyclooxygenase-2 inhibitors and vasomodulator compounds for generalized pain and headache pain | PHARMACIA CORPORATION | 2002-06-20 | — | — | US | claimed |
| WO-2002005799-A2 | COMBINATION OF A COX-2 INHIBITOR AND A VASOMODULATOR FOR TREATING PAIN AND HEADACHE PAIN | PHARMACIA CORPORATION (US) | 2002-01-24 | — | — | WO | claimed |
| US-6034256-A | CYCLOOXYGEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2000-03-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256804-A1 | PHARMACEUTICAL COMPOSITION | CYP2C19, CYP2C9, CYP3A5 | PTGS2 36/4885PTGS1 40/4885USP2 4177/4885 |
| US-20020077328-A1 | Selective cyclooxygenase-2 inhibitors and vasomodulator compounds for generalized pain and headache pain | PTGIR, VASP, TRPV2 | PTGS2 4/4885PTGS1 8/4885USP2 2000/4885 |
| US-20020103141-A1 | Antiangiogenic combination therapy for the treatment of cancer | TOP2A, TOP2B, TOP1 | PTGS2 4/4885PTGS1 6/4885USP2 2013/4885 |
| US-20160008317-A1 | THERAPEUTIC AGENT FOR OCULAR DISEASE | ALDH1A2, PDE6C, PDE6A | PTGS2 692/4885PTGS1 272/4885USP2 4439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.